Federal Register of Legislation - Australian Government

Primary content

PB 46 of 2012 Determinations/Health as made
This determination amends the National Health Act 1953 - Determination under paragraph 98C(1)(b) - conditions (No. PB 119 of 2008) to provide changes to the conditions subject to which payments will be made by the Commonwealth in respect of the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners.
Administered by: Health
Made 19 Jul 2012
Registered 25 Jul 2012
Tabled HR 14 Aug 2012
Tabled Senate 14 Aug 2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

COMMONWEALTH OF AUSTRALIA

Instrument number PB 46 of 2012

Amendment determination under paragraph 98C(1)(b) of the National Health Act 19531

 

I, Felicity McNeill, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under paragraph 98C(1)(b) of the National Health Act 1953.

 

Dated                                          19 July 2012

 

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

Amendment determination — conditions

1              Commencement                                                        

                This instrument commences on 1 August 2012.

2              Amendment of the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

                Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).



Schedule 1            Amendments

 

[1]        Schedule 1, after entry for Cefaclor with Water Purified BP in the form Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL

insert in the columns in the order indicated:

Cefuroxime with Water Purified BP

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

 

[2]        Schedule 4, after entry for Cefaclor in the form Powder for oral suspension
250 mg (as monohydrate) per 5 mL, 75 mL

insert in the columns in the order indicated:

Cefuroxime

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

 

[3]        Schedule 4, entry for Oestradiol

omit:

 

Transdermal patches 2 mg, 8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.